Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423687 | 0.86 | PREP (0.44) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL3423684 | 0.86 | PREP (0.46) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL3422387 | 0.84 | PREP (0.45) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL12244756 | 0.84 | PREP (0.45) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL12244755 | 0.83 | PREP (0.45) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL15102712 | 0.82 | PREP (0.42) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL16392607 | 0.82 | PREP (0.49) | PREPDPP8DPP7HTTKEAP1 | |
| SCHEMBL12292635 | 0.82 | PREP (0.54) | PREPDPP8DPP7HTTTGM2 | |
| SCHEMBL20218236 | 0.81 | MMP9 (0.40) | HDAC6NAMPTSLC6A1SLC6A11 | |
| SCHEMBL3426428 | 0.80 | PREP (0.54) | PREPDPP8DPP7HTTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2018-09-13 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-8796436-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130211063-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8507661-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | PREP 3782/4885DPP8 2037/4885DPP7 2805/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PREP 4740/4885DPP8 2911/4885DPP7 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.